JP2005511663A - 癌に対する医薬の製造のための、他の抗腫瘍性剤と組み合わせたファルネシルタンパク質トランスフェラーゼインヒビターの使用 - Google Patents

癌に対する医薬の製造のための、他の抗腫瘍性剤と組み合わせたファルネシルタンパク質トランスフェラーゼインヒビターの使用 Download PDF

Info

Publication number
JP2005511663A
JP2005511663A JP2003548949A JP2003548949A JP2005511663A JP 2005511663 A JP2005511663 A JP 2005511663A JP 2003548949 A JP2003548949 A JP 2003548949A JP 2003548949 A JP2003548949 A JP 2003548949A JP 2005511663 A JP2005511663 A JP 2005511663A
Authority
JP
Japan
Prior art keywords
administered
amount
day
twice
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003548949A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511663A5 (https=
Inventor
デービッド エル． カットラー，
マイケル エル． メイヤーズ，
チャールズ バウム，
サラ エル． ザッコネン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2005511663A publication Critical patent/JP2005511663A/ja
Publication of JP2005511663A5 publication Critical patent/JP2005511663A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003548949A 2001-11-30 2002-11-25 癌に対する医薬の製造のための、他の抗腫瘍性剤と組み合わせたファルネシルタンパク質トランスフェラーゼインヒビターの使用 Withdrawn JP2005511663A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33441101P 2001-11-30 2001-11-30
PCT/US2002/037954 WO2003047697A2 (en) 2001-11-30 2002-11-25 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer

Publications (2)

Publication Number Publication Date
JP2005511663A true JP2005511663A (ja) 2005-04-28
JP2005511663A5 JP2005511663A5 (https=) 2006-01-05

Family

ID=23307076

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003548949A Withdrawn JP2005511663A (ja) 2001-11-30 2002-11-25 癌に対する医薬の製造のための、他の抗腫瘍性剤と組み合わせたファルネシルタンパク質トランスフェラーゼインヒビターの使用

Country Status (13)

Country Link
US (2) US20030185831A1 (https=)
EP (1) EP1448268A2 (https=)
JP (1) JP2005511663A (https=)
CN (2) CN1617755A (https=)
AU (1) AU2002352941A1 (https=)
BR (1) BR0214564A (https=)
CA (1) CA2468839A1 (https=)
HU (1) HUP0402401A2 (https=)
MX (1) MXPA04005207A (https=)
NO (1) NO20042730L (https=)
NZ (1) NZ532562A (https=)
WO (1) WO2003047697A2 (https=)
ZA (1) ZA200403737B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533838A (ja) * 2002-07-24 2005-11-10 ノバルティス　アクチエンゲゼルシャフト 未分化甲状腺癌を処置するための４−（４−メチルピペラジン−１−イルメチル）−ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イルアミノ］フェニル］−ベンズアミド
CA2439440A1 (en) * 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
CA2544421A1 (en) * 2003-11-06 2005-05-26 Schering Corporation Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer
JP2007525507A (ja) * 2004-02-26 2007-09-06 ザ ペン ステイト リサーチ ファンデーション オピオイド増殖因子レセプターを用いる、新生物の処置のための組み合わせ療法
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20080255171A1 (en) * 2005-10-07 2008-10-16 Manley Paul W Combination of Nilotinib with Farnesyl Transferase Inhibitors
WO2008051531A2 (en) * 2006-10-25 2008-05-02 Schering Corporation Discontinuous methods of treating cancer
WO2008067144A2 (en) * 2006-11-28 2008-06-05 Smithkline Beecham (Cork) Limited Cancer treatment method
US20230390197A1 (en) * 2020-10-27 2023-12-07 Wisconsin Alumni Research Foundation Modular dendron micelles for combination immunotherapy
AU2023376684A1 (en) 2022-11-09 2025-06-19 Merck Patent Gmbh Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
DK1041985T3 (da) * 1997-12-22 2006-06-19 Schering Corp Kombination af benzocycloheptapyridinforbindelser og antineoplastiske lægemidler til behandling af profilerative sygdomme
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
JP5491681B2 (ja) * 2000-02-04 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
US6838467B2 (en) * 2000-02-24 2005-01-04 Janssen Pharmaceutica N. V. Dosing regimen
CA2397448A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
JP2003525239A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
EP1322334A2 (en) * 2000-10-05 2003-07-02 George Q. Daley Methods of inducing cancer cell death and tumor regression

Also Published As

Publication number Publication date
NO20042730L (no) 2004-06-29
WO2003047697A2 (en) 2003-06-12
AU2002352941A1 (en) 2003-06-17
ZA200403737B (en) 2005-05-23
WO2003047697A3 (en) 2003-10-30
MXPA04005207A (es) 2004-08-19
US20060183765A1 (en) 2006-08-17
CA2468839A1 (en) 2003-06-12
HUP0402401A2 (hu) 2005-03-29
EP1448268A2 (en) 2004-08-25
CN101181269A (zh) 2008-05-21
NZ532562A (en) 2007-02-23
US20030185831A1 (en) 2003-10-02
CN1617755A (zh) 2005-05-18
BR0214564A (pt) 2004-11-09

Similar Documents

Publication Publication Date Title
EP2127652B1 (en) Method for treating cancer using anticancer agent in combination
Rudin et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer
EP1622619B1 (en) Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
Mayer et al. Chemotherapy for metastatic breast cancer
CN104997808A (zh) 用于治疗癌症的方法和组合物
JP2011522773A5 (https=)
JP2003533485A5 (https=)
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
TW200533339A (en) Therapeutic synergy of anti-cancer compounds
JP6898329B2 (ja) 併用療法
KR20090040926A (ko) 암 치료용 배합 생성물
JP2021505548A (ja) 化学療法抵抗性の卵巣がんまたは乳がんの治療におけるｐａｒｐ阻害剤の使用
TW200404532A (en) Therapeutic combinations of ERB B kinase inhibitors and antineoplastic therapies
HK1248539A1 (zh) 借助塞里班土单抗的组合治疗
JP2005511663A (ja) 癌に対する医薬の製造のための、他の抗腫瘍性剤と組み合わせたファルネシルタンパク質トランスフェラーゼインヒビターの使用
JP2005511663A5 (https=)
Schöffski et al. Current role of topoisomerase I inhibitors for the treatment of mesenchymal malignancies and their potential future use as payload of sarcoma-specific antibody-drug conjugates
Wulkersdorfer et al. Pharmacokinetic aspects of vascular endothelial growth factor tyrosine kinase inhibitors
WO2020232191A1 (en) Bisfluoroalkyl-1,4-benzodiazepin one compounds for treating notch-activated breast cancer
CN103189059A (zh) 治疗耐药性癌症的方法
Saint-Ghislain et al. Adverse events of targeted therapies approved for women's cancers
MX2007013830A (es) Terapia de combinacion.
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
AU2007201079A1 (en) Methods of treating cancer using an FPT inhibitor and antineoplastic agents
Ricart et al. Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051122

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080722